In this phase 2 study, 52 patients with p53-mutated AML (n = 18) and MDS (n = 34) were treated with eprenetapopt 4500 mg IV on Days 1 to 4 combined with azacitidine 75 mg/m2 subcutaneous injections daily from days 4 to 10 of a 28-day cycle followed by consolidation with allogenic SCT. The gene discussed is TP53; the disease is myelodysplastic syndrome.